Oxford BioMedica (GB:OXB) has released an update.
Oxford Biomedica PLC reports strong demand for its cell and gene therapy CDMO services in the first half of 2024, with a revenue backlog of £113 million and contracted client orders worth approximately £80 million. Despite expecting a low double-digit Operating EBITDA loss for 2024 due to investments in talent for future growth, the company maintains a positive outlook for 2025 profitability. The firm’s multi-site, multi-vector strategy, including international expansion, reinforces its confidence in sustained growth within the burgeoning cell and gene therapy market.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.
